US Pharm. 2012;37(9):54.

The GPhA announced that it has received a positive advisory opinion from the Federal Trade Commission on the Accelerated Recovery Initiative (ARI)—the generic industry’s multistakeholder initiative predicated on voluntary communication between the FDA, the IMS Institute, and stakeholders involved in the manufacturing and distribution of critical generic medications currently experiencing a shortage. It is designed to use real-time supply and distribution information as well as manufacturers’ production and release forecasts, to provide the FDA with better insight into current critical drug-supply conditions and thus potentially avert future shortages.

The GPhA and IMS Health are now working closely with the FDA to finalize the details of the initiative and begin operation of the ARI in the near future.